Abstract: Nucleic acids have been extensively modified by replacing the phosphodiester group or the whole sugar-phosphodiester backbone with alternative anionic, neutral and cationic structures. Several of these modified oligonucleotides exhibit improved properties including enhanced recognition and binding to RNA, duplex DNA and proteins. This has resulted in the development of new and more potent antisense and antigene agents, as well as aptamers. Furthermore, backbone modified oligonucleotides have also been used in the development of several alternative strategies, which rely on altogether different mechanisms of action and show significant promise for therapeutic intervention. In this review the latest advances in the synthesis and evaluation of the most promising backbone modified oligos will be discussed, with a view to their future as novel pharmaceuticals.
INTRODUCTION
Whilst significant advances have been made in the use of modified oligos in the antisense and antigene area, equally as exciting are the more recent developments of modified oligos with alternative and novel modes of action. For example synthetic hammerhead ribozymes, capable of sequence specific cleavage of a target RNA, can stabilised in biological fluids by chemical modification [18] . Aptamers, short strands of DNA or RNA generated by in vitro selection, can be modified to improve their stability and binding affinity for therapeutically relevant protein targets [19] . Alternatively modified oligo decoys can function as structural RNA mimetics and compete with viral RNA structural elements in binding to viral regulatory proteins [20] . Furthermore, modified oligos that mimic the high energy distorted structures of dsDNA when bound to restriction enzymes, can be used as transition state analogues which effectively inhibit the binding of the native dsDNA substrates [21] . Even more provocative is the development of short modified oligos that can function as suicide inhibitors of self-splicing RNA introns from fungal pathogens, resulting in dead-end ribosomal RNAs [22] . All of these approaches could potentially lead to new therapeutic strategies and all have arisen through the systematic evaluation of the effects of chemical modifications, principally in the backbone of oligonucleotides, on the structure, conformational and biophysical properties of the oligo.
The last decade has seen an upsurge of interest in the chemistry and biology of nucleic acid analogues. This has mainly been due to the realisation that modified oligonucleotides, with improved properties, can be used in the sequence specific control of gene expression and have immense potential as therapeutic agents [1] [2] [3] [4] [5] . The principle mode of action of these modified oligos is through the binding, via Watson and Crick base pairing, to a specific mRNA sequence associated with a diseased state and the subsequent inhibition the translational event leading to a detrimental protein (antisense) [1] [2] [3] [4] . In addition, transcription can be inhibited by the binding of an oligo to duplex DNA, principally through Hoogsteen base pairing and the formation of a triple helix (antigene) [5] [6] [7] . The appeal of these approaches, particularly antisense, is the tremendous scope of these agents for use in the treatment of many diseases which are characterised by the expression of unwanted genetic material, where target selection is governed primarily by gene sequence. Thus a rational approach to the treatment of cancers, viral and bacterial infections, as well as other diseases can be envisaged. To these ends a plethora of nucleic acid analogues have been designed, synthesised and evaluated, with a view to the improving the efficacy of these agents by altering their bio-physical properties compared with native DNA and RNA [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Desirable properties include improved stability to nuclease enzymes and uptake into cells. Increased affinity, kinetics and base pairing specificity upon binding to nucleic acid targets can also improve the efficacy of these agents. For the antisense approach the ability to activate enzymes, such as RNases H or L, which are capable of irreversibly destroying a specific mRNA, is also an important factor.
As more is learnt about the effects of specific modifications on oligonucleotide structures, then the more likely it is that further novel targets and mechanisms for therapeutic intervention, will be discovered utilising modified oligos. In parallel the increased availability and diversity of synthetic modified oligos will continue to see an increase in their use as tools to investigate fundamental questions pertaining to the structure-function relationship of nucleic acids [23] [24] [25] . Moreover, modified oligonucleotides are increasingly being used to address questions concerning the origins of life. Notably, novel chemistry is being used to mimic the native nucleic acids and their inherent propensity for self-replication via template based mechanisms [26, 27] . Finally, modified oligonucleotides are also finding increasing use as probes and other tools in molecular biology, particularly for sequencing by hybridisation and medical diagnostic [28, 29] .
exploit that fact that only as few as 5 base pairs of a DNA.RNA heteroduplex are required to bind and activate RNase H [30] . These chimeras, or so called "gapmers", usually retain a central sequence of DNA, or phosphorothioate DNA (PS-oligo), flanked by alternatively modified oligos which are capable of protecting the central region from exonuclease cleavage ( Fig.  1 ). Methylphosphonate and 2´-Oalkyl modifications have been employed to good effect in terminal regions of gapmers [31, 32] .
Because of the accelerated efforts in this area of research over the last decade, it is not possible to cover the many different modifications that have been performed on oligonucleotides, nor all the potential application of these modified oligos. Therefore, this review will focus on the latest advances in the development of backbone modified nucleic acids which show greatest promise for therapeutic applications. Whilst most of the research discussed has been conducted with a view to improving the efficacy of antisense and antigene agents, where possible important examples of backbone modified oligos having alternative modes of action will be included. In this respect the review will be selective and the reader is referred to several excellent earlier reviews which cover extensively the many other types of backbone [8] [9] [10] [11] [12] [13] [14] , sugar ring [15, 16] , or base [17] modifications to oligonucleotides that have been reported.
Contrary to early opinion, activation of RNase H is not essential for potent antisense and in some cases can be detrimental, since transient complexes with partially complementary, non-target RNA, sequences can be cleaved resulting in non-specific effects [33] . Indeed several types of backbone modified oligos, which are incapable of activating RNase H, have been shown to be effective antisense agents [34, 35] . Such oligos are thought to act by a steric blocking mechanism, inhibiting the ribosome, initiation factors or other proteins from binding to specific sites on a RNA transcript. It seems likely that strong binding to the target mRNA is essential for steric blocking oligos, and that these agents are more effective when targeted to non-coding sequences, such as 5´-leader sequences or splice junctions, given that an advancing ribosome can be expected to displace an antisense oligo bound to a coding region [33] .
Therapeutic Targets and Mechanisms of Action
Translational arrest is by far the most common mode of action for therapeutic intervention by modified nucleic acids. Several distinct types of modified oligos have been developed which operate by different mechanisms and are capable of inhibiting translation. These include those oligos that activate RNase H, those that do not (steric blocking agents), those that recruit other cellular enzymes such as RNase L and finally ribozymes.
A third class of oligos capable of translational arrest are the 2-5A-antisense chimeras [36] . These chimeras consist of a 5´-monothiophosphorylated 2´→5´ linked tetraadenylate (2-5A) conjugated via a flexible alkyl spacer to an antisense DNA, or a modified oligo. 2-5A chimeras were introduced because of their ability to activate RNase L, a ubiquitous enzyme in mammalian cells, which cleaves RNA when activated by binding to 2-5A, as part of the antiviral response induced by interferons. The antisense oligo portion of these chimeras is able to direct RNase L to cleave a specific RNA sequence (Fig. 2a) . A 2-5A-antisense agent was recently shown to inhibit respiratory syncytial virus, in monkey kidney cells and human HEP-2 cells, more effectively than phosphorothioate modified oligos of the same sequence, due possibly to the higher concentration of RNase L than RNase H in the cytoplasm [37] .
RNase H is a ubiquitous enzyme that cleaves the RNA strand in a DNA.RNA heteroduplex [30] . Antisense oligos that can recruit RNase H can cleave a target mRNA in a catalytic fashion, such that one antisense molecule can effectively "knock out" several mRNA copies (Fig. 1) . It is therefore not surprising that oligos that can recruit RNase H are among the most potent antisense agents that have been developed. However, only those backbone modified oligos that most closely resemble native DNA, phosphorothioate, phosphorodithioate and boranophosphate modified oligos, can act as substrates for RNase H. This has prompted the development of chimeric (mixed backbone) oligos, which . RNase H binding to a mRNA-Gapmer heteroduplex followed by the sequence specific cleavage of the mRNA strand. Fig. (2) . a) RNase L activated by a 2-5A-antisense chimera resulting in the sequence specific cleavage of a mRNA target. b) An hammerhead ribozymes [18] . N = any nucleotide; Y = pyrimidine; P = purine; H = A, C, or U.
Hammerhead ribozymes, the smallest of the known RNA enzymes, can also catalyse the cleavage of a target mRNA sequence-specifically resulting in translational arrest [18] . These ribozymes base pair with the target RNA and fold into a well defined structure consisting of a conserved catalytic core flanked by three helical stems (Fig. 2b) [18] . Currently most advanced studies, in cell cultures and in clinical trials, are been conducted with ribozymes that are delivered endogenously, using plasmids or viral vectors to express the ribozyme within the cell. In addition, there is considerable interest in exogenous delivery, which involves administering the ribozymes directly to cells. Clearly the difficulties associated with this latter approach, effective cellular permeation and stability to enzymatic digestion, are the same as other oligo therapeutic strategies. However since ribozymes are generally larger, and RNA is more rapidly degraded in biological fluid as well as more difficult to synthesise than DNA, the technical problems are somewhat magnified. Despite this there has been some degree of success in utilising chemical modifications to improve the properties of ribozymes, whilst retaining and even enhancing their catalytic activity for therapeutic use [38, 39] . These modifications have mainly involved 2´-OH replacements in the ribose ring, which will not be covered here. However phosphorothioate backbone modifications have also been used to stabilise ribozymes. Although this technology is not yet as advanced as other antisense strategies, the prospects of utilising backbone modifications, which are discussed in this review, to improve the properties of ribozymes remains an intriguing and challenging possibility, that has yet to be explored.
invested in the search for modified, or alternative bases which can recognise all four bases pairs in dsDNA [17] .
All of the modes of action so far discussed involve the binding of modified oligos to nucleic acid targets. Often overlooked by those involved in the design and synthesis of modified oligos are protein targets for therapeutic intervention. The prospect that oligonucleotides could be used as therapeutic agents, through the binding to protein targets, came to the fore with the development of methods for the in-vitro selection of DNA or RNA ligands (aptamers), which can bind with high affinity to proteins [42, 43] . In principle, using techniques such as SELEX [43] , aptamers can be selected with high affinity for any protein target, from a pool of random DNA or RNA molecules generated and amplified using polymerase enzymes and PCR. Clearly these oligos would be unstable in vivo, and to this end aptamers can be stabilised by using 2´-fluoro or 2´-amino pyrimidine nucleoside triphosphates as substrates for in vitro selection [44] . In addition, post selection modification of aptamers has also been realised, using backbone as well as sugar modifications, without compromising the high binding affinity for the protein target [19, 44] . This therefore promises to be another area in which oligonucleotide modification can be used to improve the properties of therapeutic oligos. In addition strategies have been envisaged where modified oligos can be used as decoys [20] or transition state analogues [21] , which mimic key nucleic acid structural motifs and bind certain enzymes that are responsible for processing the native nucleic acids. Whilst efforts in targeting proteins with modified oligos have only just begun, it is clear that there are an awesome number of potentially distinct targets and mechanisms of action by which modified oligonucleotides might be used to cure disease.
Inhibition of translation by the antigene approach requires the binding of an oligo to a dsDNA target. This can be achieved by the formation of a triple helix, principally by Hoogsteen hydrogen bonding of a third strand through the formation of T.AT and C+.GC triplets, or by reverse Hoogsteen H-bonding and the formation of A.AT and G.GC triplets [5, 6] . Whilst the antigene approach has the advantage that there are fewer copies of dsDNA than mRNA and therefore in principle a lower concentration of oligo might be required to effectively block transcription, the approach is limited mainly to homopurine tracts in the major groove. Moreover triple helices are generally less stable than double helices, whilst the rate of binding of triple helix forming oligos (TFOs) to dsDNA, is several orders of magnitude slower than the binding of an oligo to a single stranded nucleic acid. Furthermore, any oligo operating in an antigene fashion must be able to penetrate within the chromatin structure of the cell nucleus [40] . These problems mean that antigene strategies have not met with the same degree of success as antisense strategies, in advanced biological studies. Despite this promising results have been achieved by improving the affinity of a triple helix forming oligos for homopurine tracts in dsDNA, using backbone modified oligos, which has led to successful transcriptional arrest in cell culture experiments [40] . Alternatively strand invasion of dsDNA, by peptide nucleic acids, has also shown significant promise in antigene approaches [41] . However, before this approach can match antisense in scope, problems associated with the recognition of dsDNA must be overcome. In this respect considerable effort has been
Design Criteria, Structure, Conformation and Synthesis
All therapeutic oligos must by stable to enzymatic degradation and pass efficiently through the cell membrane to the target site unaltered. Native oligos are not suitable for this purpose because they are rapidly degraded by extra and intracellular nucleases. In the case of oligodeoxynucleotides degradation mainly occurs through the action of exonuclease enzymes, with 3´-exonuclease occurring most rapidly. It is for this reason that backbone modification strategies were first introduced. Every modification of the backbone that has been investigated, which involves replacing the phosphodiester linkage with an alternative moiety, results in improved stability to nuclease digestion. Indeed even those modifications that most closely resemble the native structures (e.g. phosphorothioates and boranophosphates) are stabilised significantly, whereas more radical backbone modifications result in complete resistance to degradation. Efficient passage through the cell membrane presents much more of an obstacle. Although it has been speculated that increasing the lipophilicity of oligonucleotides by replacing the anionic backbone with alternative neutral moieties may result in improved cellular penetration, this has still to be proved. In fact, whilst it depends on the particular cell type that is targeted, to a large extent all modified oligos irrespective of backbone chemistry, have trouble entering the cell unaided in high concentrations. For this reason a number of delivery strategies are often employed to aid the passage of oligos into cells. These include the use of: cationic liposomes [45] ; microinjection [46] ; the bacterial toxin streptolysin O [31, 35] ; scrape loading [47] ; and conjugation to small peptides [48] that are known to be internalised within certain cell types. Whilst some of these techniques are not appropriate for human clinical studies, they have been used extensively in the efficient delivery of modified oligos in cell culture and animal experiments.
3´-O and 4´-O, which overcomes the anomeric effect (Fig.  3b) . In this respect, replacements of the phosphodiester group which result in 3´-substituent atoms with reduced electronegativity and/or incorporation of electronegative 2´-fluorine, or 2´-Oalkyl groups on the sugar ring have been used to good effect to produce modified oligos with high affinity for complementary RNA [52, 53, 54] . All of these considerations are important in the design of backbone modified oligos, however it is not possible to consider the effect of modifications with respect to one of these factor or a thermodynamic parameter in isolation, since they are all intrinsically related. Having effectively stabilised an oligo against degradation and assuming efficient delivery to the target site it is important that the modified oligo can interact with high affinity and specificity with the target. Here modification strategies have had considerable success, particularly when targeted to single stranded RNAs. In considering the effects that chemical modifications can have on binding affinity it is important to consider a simplified picture of the factors effecting the thermodynamic stability of duplexes (Fig. 3a) . The major stabilising forces in duplex formation are hydrogen bonding and base stacking (π-π stacking) interactions. Therefore base modifications that increase the number of hydrogen bond donors and acceptors, or increase the π surface area of the bases can be used effectively to improve affinity [46] . A major destabilising factor in duplex formation is electrostatic repulsion between backbones. In this case affinity can sometimes be enhanced by replacing the backbone with neutral or even cationic backbones, which alleviate the electrostatic repulsion. Often overlooked is the relative degree of hydration of the duplex. It is important that any backbone modification is favourably hydrated in the duplex states [49] . All of these factors are primarily enthalpic and contribute to a typically large overall negative enthalpy change on hybridisation, which is the driving force for native duplex formation [50] . However, hybridisation of native oligos also results in a large loss of entropy which is unfavourable. Apart from the obvious loss of rotational and translational freedom inherent in any bimolecular interaction the loss of free energy, associated with the internal bond rotations and vibrations, must also be considered. In the single stranded state the bonds are free to rotate and vibrate (random coil), but frozen out on formation of the more rigid duplex structure. By rigidifying the backbone in such a way that the single stranded state is preorganised into a helical base stacked conformation prior to hybridisation, it is possible to reduce the loss of entropy on duplex formation and increase binding affinity [50, 51] . The effects of modifications on duplex and triplex stability are usually determined by measuring duplex and triplex melting temperatures (T m ) using UV thermal analysis. Typically values for the change of T m per modification (∆T m /mod), compared with an iso-sequential native reference duplex or triplex are quoted for comparison. It is however important to point out that binding affinity can depend significantly on the particular sequence used and as many sequences as possible should be examined, including mixed sequences, before definitive conclusions are reached about the effects of a particular modification. Most studies tend to use a number of standard sequences that have been chosen for comparison and which give fairly representative results [55] .
Similar considerations to those above have also resulted in the design of modified oligos which form more stable triplexes. Once again modifications that more closely resemble the conformation of RNA and adopt C3´-endo sugar conformations, tend to form more stable triplexes, whilst alleviating electrostatic repulsion can also have good effects. Design criteria for modifying nucleic acids in order to enhance interactions with protein are less well established. Although it is important that modifications do not disrupt markedly, secondary structure that may be important for binding. In another respect, the negative charge of the phosphodiester group is more important in protein interactions, than interactions with other nucleic acids, since specific contacts between the protein residues and the phosphodiester groups are often critical for binding. In this case alternative anionic replacements for phosphodiester can In addition to these factors it is well established that backbone and sugar modifications that result in a preference for a C3´-endo or northern (N) conformation, typical of the ribose sugar in RNA duplexes, tend to result in oligos which form more stable A-type duplexes with complementary RNA [51] . In RNA it is the presence of 2´-hydroxyl which drives the pseudorotational equilibrium of the ribose ring towards the N-conformer, which is attributed to a gauche effect between 2´-OH and 4´-O (ring oxygen) combined with an anomeric effect which operates when the base is in a pseudoaxial position. In deoxyribose the absence of the 2´-OH results in a more stable C2´-endo or southern (S) conformer as a consequence of the gauche effect between be important [20] . Also, by systematically replacing phosphodiester groups with neutral linkers it is also possible to probe which phosphodiester groups are and are not critical for binding, which can allow for further site specific modifications to be investigated [19] .
non-bridging oxygen atoms, in the phosphodiester group of oligodeoxynucleotides, with a sulfur atom [58] . The resulting phosphorothioate oligos (PS-oligos) 1 (Fig. 4) have been reviewed extensively [2] [3] [4] 8] and will therefore not be discussed in detail here. PS-oligos are easily synthesised on commercial DNA synthesiser, albeit as a mixture of diastereoisomers at the phosphorus atom, and as alluded to earlier are resistant to nuclease cleavage, although less so than most other modified oligos. In addition they can act as substrates to RNase H. This has led to the widespread use of fully modified PS-oligos as antisense agent. These first generation antisense agents have been extensively tested in various human clinical trials against numerous targets. This has culminated in a PS-oligo called Vitravene (or Fomivirsen), which is used in the treatment of cytomegalovirus (CMV) induced retinitis in AIDS patients, and is the first antisense drug that has so far been approved for marketing. Despite this success PS-oligos have a tendency to induce non-specific effects, through binding to extracellular and cellular proteins [59] , as well as cleavage of non-target mRNAs, that are only partially complementary, due to activation of RNase H [33] . For these and other reasons, including low binding affinity of PS-oligos for complementary nucleic acid targets, alternative modified oligos have been sought for antisense strategies for some time. However the ease of synthesis of PS-oligos invariably means that they are frequently used against new antisense targets, or are the first to be tried in the development of alternative strategies requiring backbone modifications, such as the 2-5A-antisense agents, ribozymes and aptamers as well as other oligos designed for bind to specific protein targets. In this respect PS-oligos are the standard by which most other backbone modified oligos, with therapeutic pretensions, are measured.
Finally any modification strategy must be synthetically feasible, economically viable and rapid allowing access to sufficient quantities of material for detailed biological investigations. In this respect, it is important that the chemistry developed can be adapted for use on the solid phase, and preferably is compatible with existing synthetic procedures, most notably the phosphoramidite or Hphosphonate chemistries which are most widely used for the synthesis of native nucleic acids [56, 57] . Whilst most base and sugar modifications can be accommodated within these protocols, backbone modification present more of problem particularly if the backbone functionality is significantly removed from the native phosphodiester. As a consequence of this modified dinucleotides with 3´-phosphoramidite groups and dimethoxytrityl (DMTr) protection at the 5´-end are employed extensively in the so called "block synthesis" approach, utilising standard DNA synthesisers. However, the chimeras produced by this method may be of limited utility in therapeutic strategies where often a consecutive stretch of modifications might be required (e.g. gapmers). For this reason synthetic strategies must be developed which use appropriately activated monomer synthons, that can be coupled with efficiency approaching that with which native oligos can be assembled. This can be technically demanding and take considerable effort and time in development. For this reason several promising modifications that have displayed favourable characteristics, when incorporated into a few positions within a chimeric oligo using the block synthesis approach, have taken considerable time from conception before incorporation into relevant sequences for use in biological studies. Modified oligos can also be prepared by enzymatic procedures using polymerases and modified nucleoside triphosphates with various sugar, base and backbone modifications (e.g. boranophosphate and phosphorothioate oligos). This can be particularly important in the development of therapeutic ribozymes and aptamers, although ultimately these structure must succumb to nonenzymatic synthesis.
BACKBONE MODIFICATIONS

Anionic Internucleoside Linkage
A large number of different backbone modifications have been investigated, particularly modifications that involve retaining the sugar ring and replacing the phosphodiester linkage with alternative anionic, neutral and cationic groups. In addition to these a number of nucleic acids analogues, where the whole sugar-phosphodiester backbone is replaced by alternative functionality, have been investigated. To begin with anionic phosphodiester replacements will be discussed. 
The N3´→P5´ Phosphoramidate Modification
Oligonucleotides with phosphoramidate, as opposed to phosphodiester linkages, have been the focus of much The whole area of research concerned with backbone modified oligos began with the replacement of one of the attention. These include the negatively charged, achiral N3´→P5´ phosphoramidates 2 with a bridging 3´-amino group [60, 61] , and the oppositely orientated P3´→N5ṕ hosphoramidates 3 [62] , as well as the neutral, but chiral phosphoramidates with non-bridging amino groups 4 [63, 64] . Of these the N3´→P5´ phosphoramidates, developed by Gryaznov and co-workers, have superior biophysical properties and show greatest promise for therapeutic and other applications.
N3´→P5´
phosphoramidate oligodeoxynucleotides, including fully modified oligomers and phosphodiester chimeras, form stable duplexes with both complementary DNA and RNA [60, 61, 65] . On average duplexes with DNA and RNA, independent of nucleotide sequence and base composition, are stabilised by ca. 2.3-2.6 ˚C (increase in T m ) per modification compared with native oligos. In addition duplexes, composed of self-complimentary sequences, in which both strands are uniformly modified with N3´→P5´ linkages are similarly much more thermodynamically stable than the corresponding DNA or RNA duplexes. Furthermore N3´→P5´ phosphoramidate homopyrimidine strands form more stable triplexes with both dsDNA and dsRNA than corresponding native DNA [60, 61, 68] . By contrast the oppositely orientated P3´→N5ṕ hosphoramidate 3 [62] , and 3´NMe→P5ṕ hosphoramidates 10 [61] , with a N-methyl group replacing the bridging NH group (Fig. 6) do not base pair with either complementary DNA or RNA. Finally, it has been observed that N3´→P5´ phosphoramidates with 2´-fluoro substituents 11 [52] form even more stable duplexes with DNA and RNA, with a 4-5 ˚C increase in T m per modification. Surprisingly 2´-Omethyl N3´→P5ṕ hosphoramidates 12 form significantly less stable duplexes with RNA and DNA [49] . It is expected, in both cases, that the additional presence of 2´-electronegative groups should favour the 3´-endo sugar conformation and result in more stable A-type duplexes. 
CPG
Structural studies with a uniformly modified N3´→P5ṕ hosphoramidate duplex, of sequence d(CGCGAATTCGCG) 2 , have been carried out using X-ray crystallography [49] , molecular dynamics simulations [62, 69] as well as NMR and CD spectroscopy [70, 71] . Unlike the Dickerson-Drew DNA dodecamer of identical sequence which forms a classical B-form duplex, the modified duplex was shown by all methods to exhibit backbone torsional angles including a C3´-endo sugar conformation typical of the iso-sequential A-form RNA. Furthermore, many of the helical parameters which characterise the global duplex conformational state, derived from both X-ray and the NMR solution structures, are close to those observed for typical A-type DNA structures. The fact that N3´→P5´ phosphoramidate modified DNA is structurally much more similar to RNA than DNA, and forms remarkably stable duplexes is attributed to several factors [49, [69] [70] [71] . Firstly replacement of the 3´-oxygen of DNA with the more electropositive amino substituent, reduces the guache effect between the 3´-substituent and the sugar ring oxygen (O4´). This allows the anomeric effect between the lone pair on O4´ and the C1´-N glycosidic bond to stabilise the C3´-endo sugar conformation as opposed to C2´-endo which is typical in B-DNA. Secondly, the backbone nitrogen atom, which can adopt two possible configurations, prefers to adopt a configuration which with an idealised all staggered A-type backbone places the N-H bond in an axial position (Fig. 6a) . This conformation is stabilised because the nitrogen lone pair is positioned antiperiplanar with the P-O5´ bond allowing for a strong anomeric effect involving overlap of the nitrogen lone pair with the P-O5´ antibonding orbital (σ*). The anomeric effect further rigidifies the backbone, compared with phosphodiester linkages, by reducing the torsional flexibility Initially uniformly modified N3´→P5´ phosphoramidate oligodeoxynucleotides were synthesised on the solid phase from a CPG-supported nucleosides via a repetitive cycle involving 5´-detritylation and phosphitylation to give 5´-H-phosphonate diesters (e.g. 5 in Fig. 4 ) which can be coupled with standard protected 3´-amino nucleosides [65] . In an effort to scale up the synthesis of N3´→P5ṕ hosphoramidate modified oligos as well as chimeric oligos incorporating phosphoramidate and phosphodiester or phosphorothioate internucleoside linkages, for biological studies, Fearon et al. [66] developed a more efficient and versatile synthetic procedure. The improved synthesis (Fig.  5) , which is fully compatible with standard DNA synthesisers, takes place in the 5´→3´ direction and employs an amine-exchange reaction between a 3´-amino nucleoside 6, and a 5´-phosphoramidite monomer 7. Oxidation of the intermediate phosphoramidite product followed by capping, allows for further detritylation and elongation steps resulting in oligo 8, which can be cleaved from the support and deprotected in the standard way. Further improvements of this chemistry have resulted from the use of more highly hindered-amine phosphoramidites (e.g. 9). By virtue of increased steric bulk, these phosphoramidites 9 exchange essentially irreversibly with the support bound 3´-amino group significantly reducing the number of equivalents of phosphoramidite monomer required for efficient coupling, compared with the less hindered diisopropylamine phosphoramidites 7 [67] .
of the P-N3´ bond. Both these stereoelectronic factors serve to preorganise the phosphoramidate DNA into the required conformation for the formation of stable A-type duplexes. A third significant factor is the H-bonding qualities of the 3´-NH group, which like the 2´-OH in RNA, can serve as both donor and acceptor increasing the hydration of the backbone or, as was observed in the X-ray crystal structure [49] , the coordination to anions. This can further contribute to the conformational rigidity of the backbone and the stability of phosphoramidate modified duplexes. This model [49] also explains the poor base pairing qualities of 3´NMe→P5ṕ hosphoramidate modified oligos, which are no longer favourably solvated due to the lack of an acidic backbone hydrogen atom. Furthermore in the 2´-modified N3´→P5ṕ hosphoramidates, the presence of a small 2´-Fluoro substituents 11 allows for hydrogen bonding of water or anions, to the 3´-NH group and stable duplex formation. In contrast the destabilisation of duplexes with 2´-OMe groups is probably due to poor solvation or coordination of the 3´-NH due to steric constraints imposed by the more bulky 2´-OMe group (Fig. 6b) . This is despite the fact that in both cases the additional 2´-electronegative group increases the sugar conformational bias towards the 3´-endo sugar pucker. phosphorothioate oligos. However, unlike PS-oligos, N3´→P5´ modified oligos are unable to activate RNase H when bound to complementary RNA [73] . Presumably this is a consequence of the failure of the enzyme to recognise the more RNA like conformation of the phosphoramidate backbone in heteroduplexes.
Despite an inability to activate RNase H N3´→P5ṕ hosphoramidate oligos have shown potent antisense activity in cell culture [72, 73] and in vivo [34] , which presumably must occur by a steric blocking mechanism. Studies in various leukaemia cell lines including primary bone marrow cells from patients with chronic myelogenous leukaemia (CML), were carried out with uniformly modified N3´→P5´ phosphoramidate oligos against bcr-abl, c-myc and c-myb oncogene mRNAs [72] . This revealed a sequence-specific inhibitory effect on expression of the corresponding proteins, which was significantly more potent than the effect of iso-sequential PS-oligos. This antileukaemia effect was also examined in vivo, by treating severe combined immunodeficiency mice injected with human leukaemia cells (HL-60) [34] . Whilst both fully modified iso-sequential phosphorothioate and phosphoramidate anti c-myc oligos were both effectively taken up by the leukaemia cells and had similar tissue distributions in vivo, the survival rate of the mice treated with phosphoramidate anti c-myc oligo was significantly higher than those treated with the PS-oligos or control mismatch oligos. Other antisense studies against the human T cell leukaemia virus type-1 Tax protein [73] , showed that a fully modified phosphoramidate oligo was effective in inhibiting tax gene expression in tax-transformed fibroplasts, whereas iso-sequential RNase H activating chimeric gapmers, with terminal phosphoramidate or phosphorothioate modifications were both ineffective [73] . Finally N3´→P5´ phosphoramidate oligos were shown to amongst the best inhibitors of HIV-1 reverse transcription in vitro, compared with a series of other promising antisense oligos when target against the TAR element of HIV-1 [74] .
Triple helix forming N3´→P5´ phosphoramidate oligos have also shown significant promise in antigene based strategies due to their increased affinity for dsDNA, compared with other oligos. N3´→P5´ phosphoramidate oligos containing thymine and cytosine or guanine bases targeted against the polypurine tract (PPT) motifs of HIV proviral DNA were shown, through the formation of particularly stable triple helices, to effectively inhibit transcriptional elongation in various in vitro assay systems [75] . Further studies have shown that PPT binding phosphoramidate oligos, conjugated to a psoralen moiety are able to access, bind and cross link, after UV irradiation, to the PPT target of the HIV proviral genome within the nuclear chromatin structure in HIV-1 infected cell cultures [40] . In addition to superior qualities for binding to single and double stranded nucleic acid targets, uniformly modified N3´→P5´ phosphoramidate are stable to nuclease enzymes (e.g. snake venom phosphodiesterase (SVPD) and alkaline phosphatase), and are resistant to hydrolysis in human plasma and HeLa cell extracts for up to 8 hours [72] . Clearly stability of these oligos is due to electron donation from the 3´-amino group which renders the phosphoramidate less susceptible to nucleophilic attack. Furthermore, these single stranded phosphoramidate oligos were shown not to bind to non-specific cellular proteins as was observed to occur with In addition to antisense and antigene strategies N3´→P5ṕ hosphoramidate DNA has been shown to be useful in the development of nuclease stable therapeutic oligos with all together different targets and modes of action [20, 22, 76] . Particularly interesting is the idea that phosphoramidate modified DNA because of the conformational similarity to RNA, can function as structural RNA mimetics or "decoys" and compete with viral RNA structural elements in binding recent discovery that the hexamer d(ATGAC)rU, uniformly modified with phosphoramidate linkages, can act as a suicide inhibitor of a self-splicing group-I intron from the fungal pathogen Pneumocystis carinii a common cause of death in immunocompromised patients [22, 76] . In this approach the nuclease stable hexamer was shown in vitro to compete with an iso-sequential 5´ exon in binding to the catalytic core of the group-I ribozyme contained within the pre-rRNA of P. carinii (Fig. 8) . This binding event involves antisense basepairing to an internal guide sequence which is significantly stabilised by tertiary interactions. Once bound the modified hexamer can undergo a trans-splicing reaction, through attack by the terminal uridine 3´-OH group on the phosphodiester group between the 3´-exon and intron, leading to a dead-end product. Potentially, in vivo this would result in non-functional ribosomal RNA and would disrupt protein synthesis. Several other fungal pathogens containing similar self-splicing group-I introns could also be targeted, which makes this a particularly attractive antifungal approach given that short oligos are more easily prepared and more readily penetrate through the cell membranes.
to viral gene regulatory proteins [20] . This was tested by Gryaznov and Wilson et al. [20] who showed that N3´→P5´ phosphoramidate DNA duplexes, which are isosequential to the minimal binding duplexes of the RRE and TAR elements of the HIV-1 RNA genome (Fig. 7) , bind specifically to peptides derived from Rev and Tat proteins respectively, with affinity comparable to the parent minimal RNA ligands. Since, Rev and Tat are regulatory proteins essential for HIV-1 replication, these decoys are potential and novel anti-HIV agents. Even more provocative is the
Boranophosphate Oligos
Boranophosphate DNA 13 ( Fig. 9) , introduced by Shaw and co-workers, is derived by replacing one of the nonbridging oxygen atoms in the phosphodiester group of DNA with borane (BH 3 ) [77] [78] [79] . The boranophosphate diester is isoelectronic with phosphodiesters, isosteric with the methylphosphonate group, as well as chiral. These negatively charged oligos are highly water soluble, but more lipophilic than DNA. NMR and CD studies show that replacing the phosphodiester group in dinucleotides with the boranophosphate diester results in only a slight change in conformational characteristics, such as sugar pucker, acyclic torsional angles and base stacking [80] . Furthermore, X-ray crystal structure data for dimethyl boranophosphate, (CH 3 O) 2 P(O)BH 3 -, reveals close similarity in geometry with dimethyl phosphate, except for a longer P-B bond (1.91 versus 1.51 Å) [81] . Initially it was supposed that these modified oligos might be used in the treatment of cancers, using boron neutron capture therapy (BNCT), in addition to potential antisense and antigene applications [78] .
Boranophosphate modified DNA 13 can be prepared by solid phase synthesis using an adaptation of H-phosphonate chemistry [79, 82, 83] and enzymatically using DNA polymerases and 2´-deoxyribonucleoside 5´-(α-Pborano)triphosphates 14. The α-borano dNTPs 14 can be prepared in good yields from the cyclotriphosphate 15 ( Fig.  9) [84] . Boronation using a N, N-diisopropylamine-borane complex gives 16, which can be ring opened by hydrolysis and deprotected upon ammonolysis. The diastereoisomeric products 14 can easily be separated by HPLC, but the configuration of the α-phosphorus chiral centres have not been definitively assigned [84] . A single diastereoisomer of α-borano dGTP, tentatively assigned Rp configuration at phosphorus, was incorporated into a DNA mixed sequence 14mer by a primer extension reaction on a complementary 14mer template using a DNA polymerase which resulted in a Fig. (8) . A schematic representation of the mechanism of suicide inhibition of the self-splicing group-I introns by N3´→P5ṕ hosphoramidate hexamer d(ATGAC)rU [22] . The normal cis -splicing event follows the Pathway a → b → c → d. The trans-splicing event involves binding of the phosphoramidate oligo (outlined letters) and folding (a → e), followed by cleavage to give the dead-end product (f ). Nucleotides in bold type face represent exons, whilst the intron sequence is represented by italicised letters and the tertiary interactions resulting in the correctly folded ribozyme are signified by the dashed lines. single Sp boranophosphate linkage towards the 3´-end [85] . The duplex formed with complementary DNA exhibited a T m that was 0.7 ˚C lower than the native DNA duplex, whilst the thermodynamic parameters of hybridisation (∆G˚, ∆H˚ and ∆S˚) and duplex conformation, as determined by CD spectroscopy, were very similar to the native duplex [85] . A similar template-directed primer extension reaction was also used to synthesise a 44-nucleotide stretch of mixed sequence, fully boranophosphate modified DNA [86] . Furthermore, α-borano dNTPs were shown to be compatible with the polymerase chain reaction (PCR), allowing effective amplification of DNA incorporating boranophosphates linkages, which has been used to develop a novel PCR sequencing method that is complementary to other sequencing methods [29, 87] . Finally, the synthesis of ribonucleoside α-boranotriphosphates 17 was recently reported [88] , by an analogous route to that described above for the 2´-deoxy series (Fig. 9) . It will be interesting to see if these α-boranotriphosphates 17 are substrates for RNA polymerases allowing for the enzymatic synthesis of boranophosphate RNA 18.
Early efforts in the non-enzymatic synthesis of boranophosphate modified DNA were carried out in solution using phosphoramidite chemistry with borane-dimethyl sulfide (DMS.BH 3 ) oxidation replacing the standard oxidative step in DNA synthesis [77] . However solid phase synthesis by this method is potentially problematic due to base damage occurring during the boronation step and incompatibility of the resulting boranophosphate triesters with the standard dimethoxytrityl deprotection step. The Hphosphonate approach was found to be superior for solid phase synthesis [79, 82, 83] , since H-phosphonate diesters can be boronated after chain elongation and removal of the 5´-dimethoxytrityl group, with efficiency approaching that for the conventional oxidation step to the phosphodiester group in DNA synthesis [79] . Using this approach oligothymidine boranophosphates 22 (Fig. 10) are prepared by silylation of the H-phosphonate groups of 19 to give the more reactive trimethylsilyl phosphite triesters 20 which can be boronated with o-chloropyridine-borane complex, a milder boronating agent than DMS.BH 3 , which prevents side reactions with the base [79] . The resulting boranophosphate triester 21 is readily hydrolysed with [79] . In separate studies, T 14 fully modified boranophosphates DNA was shown to form duplexes of similarly reduced stability with d(A) 14 and r(A) 14 [83] , whilst T 15 boranophosphates DNA was observed not to hybridise [82] , albeit under slightly different conditions. These results are in contrast to the mixed sequence oligo prepared enzymatically [85] , with a single enatiotopically pure boranophosphate linkage, which might possibly be due to the effects of phosphorus stereochemistry on duplex stability. In addition hybridisation studies with polythymidine oligomers are not always representative of the effects of modifications on mixed sequence duplex stability [55] . Therefore, further hybridisation studies are required with mixed sequence boranophosphate, as well as stereopure boranophosphates oligos. These results may be forthcoming following the development of efficient solid phase synthesis protocols, and a recent report detailing a method for the stereoselective synthesis of an Sp boranophosphate dinucleoside, in 98% d.e., using a chiral auxiliary [89] .
with a bioreversible protecting group, resulting in neutral phosphotriester or phosphorothioate triester pro-drugs (prooligos). It is expected that once inside the cell the pro-oligo will be "unmasked" by ubiquitous enzymes, releasing the parent oligonucleotide (drug). In addition to being more stable to nuclease degradation these neutral pro-oligos are likely to exhibit lower non-specific binding to proteins, which is attributed largely to backbone negative charge in native and phosphorothioate modified oligos. Furthermore, it is speculated that the neutral pro-oligos would be more lipophilic, improving passage through the cell membrane.
To test these ideas Imbach et al. initially synthesised dinucleotide model systems "masked" with various bioreversible protecting groups, including those used previously with other phosphorylated drugs, and investigated their stability in biological fluids [91] . From these studies the S-acyl-2-thioethyl (SATE) group showed the most promise. SATE groups are removed by carboxyesterase mediated cleavage of the thioester group followed by episulfide formation and elimination of parent phosphodiester or phosphorothioate groups (Fig. 11a) [96] . Preliminary synthesis of SATE masked oligos was achieved by alkylation of the more nucleophilic sulfur atom in phosphorothioate linkages, centrally placed in chimeric oligo gapmers with flanking regions of methylphosphonate modifications, using appropriate alkylating agents (e.g. 23 & 24 in Fig. 11b) [93] . Due to problems envisaged with incomplete alkylation of longer oligos and desulfurization side reactions occurring during this post-alkylation procedure, more recent synthesis of SATE masked oligos was achieved using a phosphoramidite approach [96] . This involves the use of (SATE)-phosphoramidites 25, which can be incorporated into oligomers in much the same way as standard cyanoethyl phosphoramidites. However, the phosphotriester products are sensitive to bases and nucleophiles which excludes the use of standard CPGsuccinate linkers and base protecting groups. To circumvent these problems thymidine (SATE)-phosphoramidite 25, which requires no base protection, and a photo-cleavable solid support were used to synthesise pro-oligothymidylates (T 12 ) with either phosphotriester or phosphorothioate triester linkages, the later requiring oxidation with Beaucage reagent. These uniformly masked DNA and phosphorothioate pro-oligos were shown to be stable to nucleases, SVPD and calf spleen phosphodiesterases, and are stable in human serum as well as gastric juice, whilst exhibiting lower affinity to serum proteins than native oligos. Futhermore, they are effectively hydrolysed to the parent oligonucleotides in total cell extracts rich in carboxyesterases consistent with the typical intracellular environment [96] . Whilst the in vivo properties of these prooligos have yet to be determined, provided that protecting groups for the other bases (C, G & A) can be developed, which are compatible with the SATE pro-oligo synthesis, then this approach might be particularly useful for improving the efficacy of existing antisense PS-oligos, which would have altogether different pharmacokinetic/pharmacodynamic characteristics.
Although it remains to be seen if boranophosphate oligos will have the prerequisite binding affinity for nucleic acid targets of therapeutic importance, other biological properties are favourable. Firstly, boranophosphate DNA is considerably more stable to various nuclease enzymes than native DNA, and on the whole more stable than phosphorothioate DNA [79] . Secondly and particularly interesting is the discovery that boranophosphate DNA can activate E. coli RNase H and induce the cleavage of RNA [83, 90] . This significantly increases the likelihood that this modification will prove useful in antisense applications. Moreover, given that α-borano dNTPs are good substrates for DNA polymerases and PCR [29, [85] [86] [87] , it would be interesting to see if boranophosphate DNA aptamers can be generated by in vitro selection, for binding to important protein targets. Even more intriguing is the possibility that boranophosphate RNA aptamers or ribozymes might be generated by a SELEX type procedure [43] . This will depend on ribonucleoside α-boranotriphosphates 17 functioning as substrates for RNA polymerases and the efficiency of boranophosphate RNA 18 to serve as a template for reverse transcription. Provided that these criteria can be fulfilled then this would provide a potential route to boranophosphate RNA aptamers and ribozymes with improved stability in biological fluids, for therapeutic applications. Although such technology would necessitate the re-synthesis of quantities of these boranophosphate RNAs, stereospecifically using solid phase chemistry, which would be particularly challenging.
The Pro-Oligonucleotide Concept
Following from the now well established pro-drug concept, Imbach and co-workers introduced the idea of prooligonucleotides [91] [92] [93] [94] [95] [96] . In this approach phosphodiester, or phosphorothioate oligonucleotide linkages are "masked"
Clearly alternative pro-oligo strategies should also be investigated [97] . Moreover, new pro-oligo strategies need not necessarily involve bioreversible protection of phosphodiester linkage. For example, one might consider bioreversible protection of the 2´-hydroxyl group of oligoribonucleotides. Like 2´-Oalkyl modified oligos, these oligos would be expected to have increased lipophilicity and stability to nucleases, however upon in vivo deprotection would reveal oligoribonucleotides. This approach, and the SATE pro-oligo approach described above, might be particularly attractive as a method for improving the in vivo efficacy and exogenous delivery of those therapeutic ribozymes, aptamers or 2-5A-antisense agents, which may prove difficult to stabilise by alternative modification methods.
can be improved with neutral linkages, but only provided that the linkage is pre-organised into the correct conformation for binding and is favourably hydrated in the duplex state.
One of the earliest examples of a neutral oligonucleotide analogue was the methylphosphonate oligos (MP-oligos), in which one of the non-bridging oxygen atoms of the phosphodiester group is replaced by a methyl group 26 (Fig.  12) . MP-oligos have been reviewed earlier [2] [3] [4] 8] and so only a brief background will be provided along with some more recent studies. Like boranophosphate and phosphorothioate modified oligos, the phosphorus atom is rendered chiral in these oligos, which are easily synthesised, as diastereoisomers at the phosphorus atom, by standard solid phase synthetic protocols from readily available methylphosphonamidites 27 [57] . As a consequence of the ease of synthesis, and the fact that they are highly resistant to nuclease degradation, the methylphosphonates were amongst the first modified oligonucleotides to be tested as antisense agents in vitro and in vivo against targets such as herpes simplex virus (HSV) and vasicular stromatitis virus (VSV) [98, 99] . However the progress in the development of MPoligos as antisense agents, was retarded due to several
Neutral Internucleoside Linkages: Methylphosophonates
Of all the backbone modifications, those involving the replacement of the phosphodiester group with neutral linkers, out number the rest. Initially it was supposed that these more lipophilic oligos might increase the efficiency of passage into cells, whilst former the electrostatic repulsion with target nucleic acids and therefore improve affinity. Whilst the former has not been shown to be the case, affinity problems. In addition to poor aqueous solubility, fully modified MP-oligos are unable to activate RNase H and have significantly reduced affinity for complementary native nucleic acids compared with native oligos. For these reasons this modification featured less often than phosphorothioate oligos in later biological studies.
amides, alkyl, alkenyl and alkynyl chains [10, 14, 108 ]. These dinucleotide analogues were then incorporated into several DNA sequences using a block synthesis approach with modified dinucleoside phosphoramidites, resulting in chimeric backbones with alternating phosphodiester and modified linkages. The thermal stability of the duplexes formed between these chimeras and complementary RNA and DNA was then determined. Of all the modifications investigated, the two isomeric amides 31 and 32 ( Fig. 13) were the only replacements that resulted in duplexes that were as stable as native duplexes with an average change in Tm of between -0.5 and +0.5 ˚C per modification with complementary RNA [109, 110] . Interestingly the affinity for complementary DNA is somewhat lower for these amide chimeras. It is argued that restricted rotation about the amide bond, with a preference for the trans isomer, preorganises these two backbones into a conformation resembling A-type duplexes. Additional NMR [111] and molecular modelling studies [112] with modified duplexes support this hypothesis and additionally show that the amide modification in isomer 31 also results in a bias of the adjacent 5´-terminal sugar towards the C3´-endo conformation which further explains the stability of duplexes with RNA. In addition to this, favourable hydration of the amide linkage in duplexes, may also be an important factor, since it was found that substitution of the acidic amide hydrogen atom in 31 with alkyl and aryl groups reduces the affinity of chimeric oligos for RNA targets [110, 113] .
Despite these problems more recent findings have reinitiated some interest in this modification. Firstly Tidd and co-workers showed that chimeric oligodeoxy gapmers, comprising of a central sequence of RNaseH activating phosphodiester linkages with flanking regions of methylphosphonate modifications, which have no solubility problems, were efficiently able to cleave target mRNAs in vitro and in human cell cultures [100] . Notably, the same group recently showed that the methylphosphonatephosphodiester gapmers, were more effective antisense agents against c-myc mRNA in human leukaemia cells following treatment with streptolysin O, than other promising antisense agents including similar gapmers with flanking regions of 2´-Oalkyl modifications and phosphorothioate oligos with C5-propyne pyrimidine modifications [31] . Similar methylphosphonate antisense gapmers against bcrabl mRNA combined with streptolysin O delivery are currently being used in clinical trials with patients suffering from chronic myeloid leukaemia [101] . A second major factor which has maintained interest in methylphosphonates was the discovery that oligos with Rp configured methylphosphonate linkages 28 have higher affinity for complementary DNA and RNA than the Sp configured diastereoisomers and in some sequences exhibit virtually the same T m as native DNA duplexes [102, 103] . In light of this approaches towards the stereocontrolled synthesis of Rp configured MP-oligos have been investigated [104] , but so far effective methods are limited to dinucleosides [105] .
Given that the amide backbone of type 31 are synthetically more accessible, further modifications to this system were carried out. For example additional 2´-methoxy groups in dimer 33, which restricts both sugars to C3´-endo conformations, contribute to an increase in T m with complementary RNA of between 2-3 ˚C per dimer modification [53] . Furthermore, an additional C5´-methyl group (S configuration) 34 rigidifies the backbone further, which when combined with 2´-methoxy groups as in dimer 35 results in a dramatic increase in T m of up to 4.4 ˚C (∆T m /mod) with RNA complements [114] . Clearly the latter Finally, two interesting variants of MP-oligos have recently been introduced, the α-anomeric methylphosphonates 29 [106] and the methanephophonamidates 30 [107] which are N3´→P5Ṕ hosphoramidate-methylphosphonate hybrid structures. In the former, inversion of the anomeric configuration was shown to improve the affinity of MP-oligos for complementary single stranded DNA and RNA as well as double stranded DNA [106] . Whilst in the latter case DNA incorporating between one and four modified linkages 30 of either configuration (Rp or Rs) showed reduced affinity for single stranded DNA and RNA targets [107] . However, one unassigned stereoisomer, showed improved affinity for dsDNA. Both modifications 29 and 30 are under further investigation as potential triple helix forming oligos for antigene strategies. system 35 is optimally preorganised into the required Atype conformation for stable heteroduplexes with RNA. Despite these promising results no biological studies have been reported for these modified oligos. This is most likely due to the fact that synthesis of biologically relevant sequences, for antisense experiments, is not best achieved using the block synthesis approach. However, a synthetic method which is compatible with standard solid phase DNA synthesis has recently be developed which utilises nucleoside pentafluorophenyl esters 36 [115] . These monomers can be used to synthesise mixed sequence fully modified amide linked oligomers or chimeras with continuous regions of phosphodiester as well as amide linkages and should facilitate long awaited biological studies with this class of modified oligos. efficient solid phase synthesis of fully modified MMI oligos [117] . Their procedure (Fig. 14) depends upon 5d eprotection of the CPG linked 5´-Ophthalimidonucleosides 39 to reveal the 5´-O-amino group of 40 which is coupled, under mild acid catalysis, with the 3´-aldehyde 41 resulting in an oxime dimer 42. A repeat of the cycle gives oxime oligomers, with a coupling efficiency of 96-99 %, which can be cleaved from the support and base deprotected under standard conditions. Reduction of the oxime and backbone N-methylation gives the fully modified MMI oligos 45. In addition MMI/phosphodiester or phosphorothioate chimeras can be prepared from oligooximes 44, derived from a tert-butyldiphenylsilyl (TPS) protected nucleoside monomer 43, by desilylation and coupling with standard phosphoramidite monomers. MMI/phosphorothioates antisense gapmers, synthesised by this method, were shown to inhibit the expression of protein kinase C-alpha (PKC-α), an anticancer target, as effectively as iso-sequential phosphorothioate oligos [117] . Further biological studies with MMI oligos are currently in progress.
Methylene(methylimino) Linkages
In parallel studies at ISIS, Sanghvi and co-workers [116, 117] have investigated several other neutral achiral phosphodiester replacements, culminating in oligos incorporating the methylene(methylimino) (MMI) linkage 37 (Fig. 14) . A block synthesis approach was also used to construct MMI / phosphodiester chimeric oligos, which showed similar affinity for complementary RNA, as the amide modified oligos, with a change in T m per modification, of between -0.2 and + 1.5 ˚C compared with native DNA [116] . The affinity for RNA can be further increased by as much as + 3.8 ˚C (∆T m /mod) by the additional incorporation of electronegative groups at the 2ṕ osition 38 [54, 118] . NMR and modelling studies with MMI dimers also revealed that the MMI linkages are restricted in conformation to either of two low energy structures which differ in the orientation of the N-methyl group, both allowing the bases to take up a stacked helical conformation for base pairing [119] . Again the presence of a less electronegative C3´-methylene group also gives rise to a preference for the C3´-endo conformation in the 5´-terminal sugar, which is further enhanced by 2´-electronegative modifications 38 [120] . To facilitate access to biologically relevant sequences ISIS have also developed an
Formacetal and Thioformacetal Linkages
In addition to amide and MMI other neutral modifications that are well accommodated within nucleic acid duplexes include the formacetal 47 and 3´-thioformacetal 48 phosphodiester replacements (Fig. 15) , which are restricted in rotation freedom, by an anomeric effect [121] [122] [123] [124] [125] [126] . Whilst the formacetal modification 47 has been shown to induce a preferred C2´-endo sugar conformation, resulting in more favourable binding to ssDNA, the thioformacetal modification 48, incorporating the less electronegative C3´-sulfur atom, prefers C3´-endo sugar pucker and forms more stable duplexes with ssRNA. These findings have earmarked the thioformacetal modification as potentially useful for antisense applications, but progress in this direction as yet to be reported. However, one altogether different therapeutic application of formacetal modified oligos was recently reported [19] . This arose from the earlier discovery of a DNA aptamer, generated by in vitro selection, isomeric 3´-N-sulfamates 54 and related sulfamides 55 [131, 132] . Accordingly dimers were synthesised and between one and five modifications were incorporated into a standard sequence of DNA [55] . This revealed that the sulfamides result in lower affinity for complementary DNA and RNA (ca. -3 ˚C ∆T m /mod), whilst the 3´-Nsulfamates have approximately the same affinity as native DNA [131] . The 3´-N-sulfamates are similar to the N3´→P5´ phosphoramidate in that the 3´-amino group which is less electronegative than the native 3´-oxygen results in a bias of the sugar pucker towards the C3´-endo conformation [132] . Binding studies of 5´-N-sulfamates with complementary RNA have not been reported, but merit exploration. However, it can be expected that the 3´-Nsulfamates will have higher affinity for RNA because they are more likely to be preorganised in the required conformation for A-type duplexes. which binds with high affinity to thrombin [42] . The minimal binding domain of the aptamer d(GGTTGGTGTGGTTGG) forms a chair-like structure 49 in which two stacked G-tetrads are connected by two T 2 loops and TGT loop. Despite a short half-life the aptamer has potent in vivo anticoagulant properties. By systematically replacing each of the phosphodiester linkages with formacetal linkages 47, using block synthesis, those positions where negative charge is essential for binding to thrombin were determined by measuring the thrombin inhibitory activity of the modified aptamers in vitro. From this a modified aptamer with four formacetal groups was selected and shown to have an increased anticoagulant effect and an extended half-life in monkeys, compared with the parent aptamer. This report opens up the possibility that other phosphodiester replacements which cause minimal disruption to the conformation of native DNA and RNA might also be used to stabilise, and even improve the binding affinity of other aptamers which have been selected for binding to medically important protein targets. Despite poor affinity for complementary nucleic acids the dimethlene sulfone modification 50 has been particularly insightful in other respects [21, 25, [133] [134] [135] . Studies on short RNA analogues with sulfone linkages (rSNA) has revealed that their physical properties and chemical reactivity is highly dependent on sequence and as such rSNAs more closely resemble proteins than nucleic acids [25, 133, 134] . The further consequences of replacing the phosphodiester with neutral sulfones has also prompted a re-examination of the role of the anionic backbone in the structure and function of nucleic acids [25, 134] .
Furthermore, X-ray crystallographic studies with sulfone dinucleotide analogues reveal distorted backbone conformation, considerably removed from native duplex conformations [24, 13] , which probably explains the dramatic drop in affinity of DNA incorporating the sulfone linkage for complementary nucleic acids. Remarkably this preorganisation of a dimethylene sulfone linkage into a distorted conformation results in a bend in DNA duplexes, incorporating a sulfone linkage, which resembles the high energy conformation of duplex DNA transition states when bound to restriction enzymes such as Eco RV [21] . This fact was used to design duplex DNA with a sulfone linkage in the Eco RV recognition site. The resulting modified bent duplexes are not substrates for the restriction enzymes, but instead are transition state analogues which act as efficient inhibitors of the native substrates [21] .
Backbones Containing Sulfonyl Groups
A number of modifications have been introduced involving replacing the PO 2-group of native oligos with neutral isosteric and isoelectronic SO 2 groups. These include dimethylene sulfones 50 [25, 127] , sulfonamides 51 [128] , sulfonates 52 [129] , 5´-N-sulfamates 53 [130] , 3´-Nsulfamates 54 [131] and sulfamides 55 [132] (Fig. 16) . Oligos incorporating these linkages have been prepared from dinucleoside phosphoramidites using the block synthesis approach and the thermal stability of duplexes have been determined. In most of these cases duplex stability is diminished significantly, with the exception of the sulfamates. The most destabilising is the dimethylene sulfone group 50 which results in a dramatic drop in T m of duplexes with both DNA and RNA (ca. -15 ˚C ∆T m /mod) [127] , followed by sulfonamides 52 (ca. -5 ˚C ∆T m /mod) [128] , which suggest that these modifications will not be useful in antisense or antigene experiments. An early paper on 5´-N-sulfamates 53, reports the incorporation of one sulfamate linkage into each of two complementary mixed sequence DNA 20mers, resulting a drop in T m of -1.5 ˚C per modification [130] . Despite this no further reports have been published. This prompted an investigation into the Many enzymes and proteins bind to specific DNA sequences resulting in bends or other conformations which are ordinarily high energy and therefore unpopulated in the native unbound state. This opens up the intriguing possibility that backbone modification such as dimethylene sulfone, which may not be useful in the antisense or antigene approaches, but mimic the distorted high energy transition states of nucleic acids when bound to various proteins, can instead be used to develop a novel class of biologically active agents that inhibit the function of key nucleic acid binding proteins. Further developments in this area can be expected due to the increase in detailed NMR and X-ray structures of native nucleic acids bound to various proteins, as well as various backbone modified nucleic acid analogues [24] . the pentamer does not show any hyperchromic shift with non-complementary homooligomers. The extremely high stability of DNG duplexes and triplexes with DNA as well as RNA, is mainly attributed to electrostatic attraction between the oppositely charged complementary backbones. As expected the stability decreases with an increase in salt concentration, due to attenuation of the electrostatic attraction. Kinetic studies have also revealed that the rate of triple helix formation between DNG (T 5 ) with short oligodeoxyadenylates, is an order of magnitude faster than the formation of DNA triplexes at similar salt concentrations [146] . Also, investigations with DNG (T 5 and T 8 ), show that T m 's are significantly reduced by base pair mismatches [147, 148] . This suggest that sequence specific base pairing is the predominant mode of binding between DNG and nucleic acid targets, although it has still to be established whether or not this is accompanied by any non-specific binding, via salt bridges, between the oppositely charged backbones. Clearly such a mode of non-specific binding, involving direct contact between the backbones of DNG and nucleic acids, could be detrimental for antigene and antisense applications. Since these interactions may not necessarily be accompanied by a change in base-stacking, methods other than UV melting experiments (e.g. surface plasmon resonance), may be required to prove that base pairing is the exclusive mode of binding. In this respect further investigation into the binding properties DNGs with RNA and DNA targets of mixed sequence, are required before the potential of this system can be fully appreciated. Such studies appear close at hand with the development of an efficient solid phase synthetic method for the synthesis of DNG (Fig. 18) [148] . The synthesis involves the coupling of a 3´-amino nucleoside 58, immobilised on a polystyrene resin, with a 5´-carbodiimide intermediate which is derived from the thiourea 59, upon treatment with HgCl 2 . Removal of the 3´-Fmoc protecting group, allows for further elongation with monomer units 59. The resulting oligomer 60 is then cleaved from the resin with mild acid and the guanidine acyl protecting groups are removed using cadmium in acetic acid.
Positively Charged Deoxyribonucleic Guanidine (DNG) Oligos
Several groups have reported the synthesis of zwitterionic and cationic oligodeoxynucleotides with pendant alkylamino side chains attached to the 2´-position of the sugar ring [137] , C5-position of pyrimidine base [138] , or to various phosphorus internucleoside linkages [139, 140] . These pendant amino groups, which are protonated at physiological pH, can in some cases form salt bridges with phosphodiester groups in complementary nucleic acids, alleviating electrostatic repulsion and allowing the formation of stable duplexes and triplexes with complementary nucleic acids, whilst retaining good aqueous solubility.
Remarkably, only a few de novo modified oligos have been reported with positively charged backbones replacing the native backbone [140, 141] . By far the most interesting are the deoxyribonucleic guanidine (DNG) oligomers, introduced by T. C. Bruce and co-workers [143] [144] [145] , in which the phosophodiester group is replaced by a positively charged guanidinium group 56 (Fig. 17) . Pentameric thymidyl DNG oligomers have been shown to bind with poly(rA) and poly(dA), with higher affinity than any other modified oligonucleotide so far investigated. The pentamer binds in a 2:1 triple helical fashion, as evidenced by two hyperchromic shifts in the UV melting curves, corresponding to the melting of the triple and double helical structures [143] [144] [145] . Remarkably at low salt concentration DNG/DNA or RNA duplexes have been shown to be stable at temperatures approaching the boiling point of water, whilst Finally, in addition to DNG, Bruce et al. [149, 150] have also reported the synthesis of pentameric thymidyl oligomers, with positively charged methylated thiourea linkages 57 (Fig. 17) replacing the phosphodiester group. These oligomers which are more hydrophobic than the DNG oligomers, also form duplexes and triplexes with DNA and RNA which are much more stable than the corresponding native structures, albeit the affinity is slightly less when compared with the prototype DNG. 
Whole Backbone Replacements: Morpholino Oligos
Although conceptually straightforward, retaining the ribose or deoxyribose sugar and investigating alternative linker groups has some limitations. In most cases the appropriate activated monomer units require several synthetic steps from relatively expensive deoxyribonucleoside precursors and even where cheaper ribonucleosides are used 2´-protection or 2´-modifictions necessitate several expensive extra steps. Furthermore, it is technically challenging to develop efficient coupling chemistry for solid phase synthesis of oligomers, particularly if the chemistry is significantly different to that used to prepare native oligonucleotides or peptides on solid supports. This makes the synthesis of some of the modified oligos discussed so far both expensive and time consuming. As a result the synthesis of sufficient quantities of some of these oligos for biological evaluation has been the major "bottle-neck" which has prevented the further exploitation of initially promising bio-physical properties. In this respect oligos, with radically altered structures in which both the sugar and phosphodiester linkage are replaced by alternative functionality, most notably morpholino oligos and peptide nucleic acids (PNA), offer several advantages over some of the modifications mentioned thus far.
form heteroduplexes with complementary RNA which are more stable than the corresponding native DNA.RNA duplexes.
Fully modified morpholino oligos have been shown to be more effective antisense agents than iso-sequential PSoligos in cell-free systems and in various cultured cells using the scrape-loading method to allow for efficient cellular uptake [47, 153] . This is attributed to the fact that morpholino oligos, do not bind to non-specific proteins, like PS-oligos, and also are much more sequence specific, because they depend on a steric blocking mechanism and do not activate RNase H, which can result in cleavage of many partially complementary sequences other than the target sequence. In one notable study morpholino oligos were shown to be more effective than PS-oligos as sequence specific antisense inhibitors of the tumor necrosis factor-α (TNF-α) in mouse macrophages, despite poor uptake into these cells [154, 155] . Most recently, a 28-mer morpholino oligo targeted at c-myc pre-mRNA, overlapping with the initiation codon, was shown to completely inhibit c-MYC protein expression in several human leukaemia cell lines, following treatment with streptolysin O [35] . Particularly interesting was the fact that the morpholino oligo, in addition to inhibiting splicing, also induces missplicing of the c-myc pre-mRNA giving rise to a translatable mRNA which results in a shorter, N-terminal deleted, MYC protein. In contrast, an iso-sequential fully modified 2´-methoxyethoxy oligo, which has high affinity for complementary RNA and is also incapable of activating RNase H, did not result in inhibition of translation, splicing or induce missplicing of c-myc pre-mRNA in the same cell Oligos with morpholino nucleosides linked together by phosphorodiamidate groups 61, are cheaper and more efficiently assembled than many of the other promising modified oligos [33, 151] . Morpholino nucleosides 63 are prepared from ribonucleosides 62 (Fig. 19) , with base protecting groups, in an high yielding one-pot procedure involving diol cleavage with sodium periodate, followed by ammonolysis of the intermediate dialdehyde and reduction with sodium cyanoborohydride. N-tritylation and phosphitylation provides a monomer unit 64 that can be used to synthesise oligomers on a solid support with a coupling efficiency of 99.7%. Fully modified morpholino oligos, unlike some fully modified neutral oligos, have good aqueous solubility and as expected are extremely stable to degradation in biological fluids [152] . Despite possessing a chiral phosphorodiamidate linker morpholino oligomers Fig. (19) . Synthesis of morpholino oligos.
lines. These favourable results, combined with the low production costs, have prompted more in depth evaluation of the properties of morpholino oligos in vivo.
reveals an altogether unusual structure (P-type) which is much wider (28 Å) and has a larger pitch, of 18 base pairs per turn, than native A-or B-type duplexes [166] . This suggests that the PNA backbone is more flexible than native nucleic acid backbones allowing it to adapt to A-, B-and P-type conformations. Therefore PNA can not be viewed as optimally preorganised, for binding to either RNA or DNA, despite the high stability of resultant heteroduplexes. It can therefore be expected that structural modifications to the PNA backbone, rigidifying the structure into an optimal conformation for binding to nucleic acids, should improve further the stability of heteroduplexes. So far most attempts to do this have failed and the prototype PNA structure 65 still remains one of the best systems for selective hybridisation with a target RNA sequences [159, 163] . This combined with resistance to degradation, by both nuclease and peptidase enzymes, has led to considerable efforts to develop these molecules as antisense therapeutics [28, 160, 161] .
Peptide Nucleic Acids
Peptide Nucleic Acids (PNA) 65, developed by Nielsen and co-workers [156, 157] , are a remarkable example of a simple, neutral and achiral whole backbone replacement, which in many ways have surpassed other attempts to mimic the native nucleic acid structures in terms of molecular recognition properties (Fig. 20) . It is not possible to review all the work in the PNA area, for this the reader is referred to the many original reviews on PNA synthesis, structure, properties and applications [158] [159] [160] [161] [162] [163] . However no review, on backbone modified oligonucleotides, would be complete without a discussion of these molecules and so following a brief introduction to the important properties of PNA the latest advances in the therapeutic applications of PNA will be discussed.
Homopyrimidine PNAs also form (PNA) 2 .DNA triplexes with extremely high thermal stability. Remarkably, as a consequence of this, homopyrimidine PNAs targeted to purine tracts of dsDNA invade the duplex by displacing one of the DNA strands and form a triple helix, with one PNA stand binding by Watson and Crick base pairing in an antiparallel orientation and the other binding in a parallel Hoogsteen fashion. The resulting stable structures are called P-loops 66 (Fig. 20) . The efficiency of this strand invasion can be further increased using bis-PNAs, consisting of two homopyrimidine PNA oligos connected via a flexible linker 68. bis-PNAs have increased affinity presumably because of a reduction in the loss of entropy upon binding compared with formation of a termolecular P-loop 66. Furthermore, bis-PNA with pseudoisocytosine bases 67, instead of cytosine bases on the Hoogsteen half, bind more tightly to dsDNA independently of pH. Recent evidence suggests, that strand invasion by bis-PNA is likely to occur by a two step process where the Hoogsteen H-bonds form first to give a PNA.(DNA) 2 intermediate 69. This is then followed by Watson and Crick base pairing and strand invasion, resulting in the bimolecular P-loop 70 [167] . Clearly this PNA consists of N-(2-aminoethyl)glycine units with the bases attached via a side chain amide linkage. The two amide groups in each monomer, in addition to a gauche effect between the two backbone NH groups, infer some rigidity on the acyclic backbone. The amide groups also facilitate the relatively straight forward synthesis of monomers and then oligomers using solid phase peptide synthesis methods. PNA oligomers are poorly soluble in water and for this reason a lysine residue is usually attached to the C-terminal end. PNA forms duplexes with complementary RNA and DNA that are considerably more stable than the native duplexes. Furthermore, PNA.DNA and PNA.RNA duplexes exhibit equivalent or in some cases lowered tolerance for base pair mismatches compared with the native duplexes. This means that the binding specificity of PNA, for complementary nucleic acids, is at least as high as DNA. Structural studies, using NMR, on PNA.nucleic acid heteroduplexes indicate that PNA is able to adopt both A-and B-type structures with RNA and DNA respectively [164, 165] . In contrast, an X-ray structure of a PNA 2 duplex unique property has earmarked PNA has a potential antigene agent [28, 160, 161] .
where much less promising, due to poor uptake, which suggests that the efficacy of these approaches will be hampered by cell wall permeability problems similar to those experienced with eukaryotic cell cultures. Research into the development of PNA antisense agents has met with some success and several groups have reported effective inhibition of the translation of various target RNAs in cell cultures [45, 168] . Notably antisense PNAs were designed to bind to the RNA component of human telomerase, a ribonucleoprotein responsible for maintaining telomeres, which is implicated in the proliferation of tumors [45] . In these studies the antisense PNAs inhibited telomerase activity, after they were first hybridised with a partially overlapping DNA strand which allowed for efficient delivery into a human prostrate tumor cell line using cationic liposomes. In addition, there have been recent reports of successful antisene experiments using PNA in animals. In one study PNA 21mers conjugated to a specific transporter protein and targeted to the galanin-receptor mRNA of rats were effective in reducing the number of galanin receptors, in the dorsal horns of the rat's spinal cord, following intrathecal administration [48] . This was evident by a decrease in the number of galanin binding sites, as demonstrated by an electrophysiological response in the rats. The effective in vivo antisense response in rats was attributed to efficient delivery of the PNA, which is facilitated by a short transporter proteins called pAntp. This protein belongs to class of related proteins which are known to be effectively internalised by living cells [169] . In other studies, shorter unmodified PNAs targeted at opiod (mu) and neurotensin (NTR-1) receptor mRNAs, where microinjected into the brains of rats. The behavioural responses of the rats to morphine and neurotensin, along with competitive binding assays with neuronal homogenates from sacrificed rats, were consistent with a reduction of receptor sites due to an antisense mechanism [170] . Further studies, also showed that same "naked" antisense PNAs were effectively able to cross the blood-brain barrier and inhibit translation of NTR-1 mRNA, following intraperitonial injection into rats [171] . These results suggest that PNA antisense agents, with and without carrier proteins, can be effectively used in vivo, at least when targeted to neuronal cells. Two recent studies also report effective antisense experiments in E. coli. In the first study, PNAs targeted at β-galactosidase and β-lactamase mRNA showed inhibition of enzyme production in an antibiotic permeable E. coli strain, that was transformed with the β-lactamase gene which confers resistance to the β-lactam antibiotics (e.g. ampicillin) [172] . Furthermore the inhibition of β-lactamase activity was sufficient to re-sensitize the bacteria to ampicillin. In the second report, bis-PNAs designed to bind in a triplex fashion to ribosomal RNA targets of the same permeable E. coli strain, were shown to inhibit protein synthesis and bacterial growth. This antibacterial effect was as strong as that of the antibiotic tetracycline, which also functions by binding to rRNA [173] . These reports offer exciting prospects that PNAs and possibly other modified oligos might be used in antibiotic treatments, either by blocking expression of resistance genes combined with conventional antibiotics, or by the specific disruption of bacterial ribosome function. These prospects are particularly appealing in light of the ever increasing threat caused by the evolution of "super bugs" with resistance to known antibiotics. It should be pointed out that the results with wild type E. coli Considerable effort has been invested in the development of PNAs and bis-PNAs as antigene agents. Several in vitro studies have shown that the binding of PNA, or bis-PNA to dsDNA can block replication [174] , transcriptional elongation [175, 176] and inhibit other proteins which bind to dsDNA including helicases [177] which are thought to precede polymerases. Nevertheless, there is some concern that antigene PNAs would be less effective than antisense PNAs as consequence of poor kinetics. Strand invasion of dsDNA is particularly slow at physiological salt concentration [176, 177] . However, efforts in this direction have not be deterred, particularly given that it has been shown that the rate of PNA binding to dsDNA is increased by a passing RNA polymerase [176] , and regions of negative supercoiled DNA [179] . It can therefore be expected that PNA strand invasion may be faster and more efficient in vivo, due to distorted DNA topology occurring during transcription and replication in the nuclear environment [178] . To some extent this has been born out and a few studies have reported transcriptional arrest, in human cell cultures [41, 180] and in animals [171] , using PNAs targeted to dsDNA. One study reports a 10 fold increase in the mutational frequency of the supFG1 gene targeted with bisPNAs, following introduction into mouse fibroblasts [41] . Remarkably in another report, a "naked" mixed purine/pyrimidine sense PNA was shown to reduce NTR-1 mRNA levels by 50% following direct injection into the brains of rats [171] . It is difficult to see how this particular PNA sequence could form stable complexes with dsDNA, by conventional triple helix binding or strand invasion, unless the target gene is distorted or transiently opened in vivo.
CONCLUSION
This review has focused on the major chemical and biological advances in the development of backbone modified oligonucleotides as therapeutic agents. Phosphorothioate modified oligos have evolved furthest with the notable advent of the first antisense drug. Several more recent modifications most notably N3´→P5ṕ hosphoramidate, PNA and morpholino oligos have been shown to be equally, if not more, effective as antisense agents in eukaryotic as well as prokaryotic cell culture, and in animal experiments. Despite an inability to activate RNase H, all of these oligos exhibit enhanced binding affinity, increased stability in biological fluids, and reduced non-specific effects. In addition PNA and morpholino oligos are likely to be more economically viable in the long term, due to ease of synthesis from cheaper starting materials. Furthermore N3´→P5´ phosphoramidate and PNA, because of their superior qualities for binding to dsDNA targets, have also been employed effectively as antigene agents in cell culture experiments.
The use of backbone modifications in the development of alternative strategies, with therapeutic potential has been equally as encouraging. Again the N3´→P5´
phosphoramidates have been particularly useful, showing promise as novel antifungal agents which function as suicide inhibitors of self-splicing introns in fungal pathogens. Phosphoramidate modified DNAs are also structural RNA mimetic and by acting as decoys, which bind HIV regulatory proteins, show promise as novel anti-HIV agents. Neutral phosphodiester replacements, formacetal and dimethylene sulfone, have also been used effectively in the development of DNA aptamers and dsDNA transition state analogues that can bind to protein targets. In addition it can be envisaged that backbone modifications might also be used to improve the properties of ribozymes for therapeutic application.
Detailed studies of the effects of backbone modifications on the conformational, physical and biological properties of nucleic acids are of crucial importance in realising the therapeutic goals. These studies have been enabled by new and improved methods for the solid phase synthesis of backbone modified oligos. Most recently MMI, DNG and amide linked oligos have all been prepared with efficiencies approaching that achieved in the synthesis of native nucleic acids. Whilst boranophosphate DNA has succumbed to efficient synthesis by both enzymatic and solid phase methods. It can be expected that the availability of these and other modifications will provide further ammunition for improving the efficacy of antisense and antigene agents, in addition to developing new modes of action through which modified oligonucleotides can have beneficial therapeutic effects.
